Oncoapoptotic signaling and deregulated target genes in cancers: Special reference to oral cancer

Biochimica et Biophysica Acta - Reviews on Cancer

Volumn 1836, Issue 1, 2013, Pages 123-145

  Khan, Zakir ^a,b,c   Bisen, Prakash S ^c,d,e  

^a CNRS   (France)

^b INSTITUT CURIE   (France)

^c JIWAJI UNIVERSITY   (India)

^d DEFENCE RESEARCH AND DEVELOPMENT ESTABLISHMENT   (India)

^e Cancer Hospital and Research Institute   (India)

Author keywords

Bcl2 family proteins; EGFR; Oncogenes; Oral cancer; TNF receptors; Tumor suppressor genes

Indexed keywords

AFATINIB; ANGIOGENESIS INHIBITOR; ANTINEOPLASTIC AGENT; APOPTOSIS INDUCING FACTOR; BEVACIZUMAB; CETUXIMAB; CISPLATIN; CYCLOOXYGENASE 2 INHIBITOR; DOCETAXEL; EPIDERMAL GROWTH FACTOR RECEPTOR KINASE INHIBITOR; ERLOTINIB; FLUOROURACIL; GEFITINIB; HYDROXYUREA; KETOROLAC; LAPATINIB; ONCOPROTEIN; OXALIPLATIN; PACLITAXEL; PLACEBO; PROTEIN BAX; PROTEIN P53; RETINOBLASTOMA PROTEIN; SORAFENIB; SUNITINIB; TENIPOSIDE; TRANSCRIPTION FACTOR E2F; TUMOR SUPPRESSOR PROTEIN; UNINDEXED DRUG; VANDETANIB;

ADVANCED CANCER; ALCOHOL CONSUMPTION; APOPTOSIS; BREAST CANCER; CANCER COMBINATION CHEMOTHERAPY; CANCER GROWTH; CANCER RADIOTHERAPY; CARCINOGENESIS; CELL IMMORTALIZATION; CHROMOSOME REARRANGEMENT; DRUG EFFECT; DRUG EFFICACY; DRUG TOLERABILITY; ENZYME MECHANISM; GENE ACTIVATION; GENE AMPLIFICATION; GENE MUTATION; GENE TARGETING; GENETIC DISORDER; HEAD AND NECK SQUAMOUS CELL CARCINOMA; HERPES SIMPLEX VIRUS; HOMEOSTASIS; HUMAN; LUNG NON SMALL CELL CANCER; METASTASIS; MOLECULAR PATHOLOGY; MOLECULARLY TARGETED THERAPY; MOUTH CANCER; MOUTH SQUAMOUS CELL CARCINOMA; NONHUMAN; ONCOGENE; ONCOGENE C MYC; ONCOGENE RAS; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTO ONCOGENE; RECURRENT CANCER; REVIEW; RISK FACTOR; SIGNAL TRANSDUCTION; TOBACCO; TUMOR SUPPRESSOR GENE; TUMOR VASCULARIZATION; WART VIRUS;

ANIMALS; ANTINEOPLASTIC AGENTS; APOPTOSIS; APOPTOSIS REGULATORY PROTEINS; CELL TRANSFORMATION, NEOPLASTIC; HUMANS; MOUTH NEOPLASMS;

EID: 84877910937     PISSN: 0304419X     EISSN: 18792561     Source Type: Journal    
DOI: 10.1016/j.bbcan.2013.04.002     Document Type: Review

References (260)

1. Bild A.H., Yao G.J.T., Chang Q., Wang Q., Potti A., Chasse D., Joshi M.B., Harpole D., Lancaster J.M., Berchuck A., Olson J.A., Marks J.R., Dressman H.K., West M., Nevins J.R. Oncogenic pathway signatures in human cancers as a guide to targeted therapies. Nature 2006, 439:353-357.
2. Chow A.Y. Cell cycle control by oncogenes and tumor suppressors: driving the transformation of normal cells into cancerous cells. Nat. Educ. 2010, 3:7.
3. Sah N.K., Khan Z., Khan G.J., Bisen P.S. Structural, functional and therapeutic biology of survivin. Cancer Lett. 2006, 244:164-171.
4. Khan Z., Khan N., Varma A.K., Tiwari R.P., Mouhamad S., Prasad G.B.K.S., Bisen P.S. Oxaliplatin-mediated inhibition of survivin increase sensitivity of head and neck squamous cell carcinoma cell lines to paclitaxel. Curr. Cancer Drug Targets 2010, 10:660-669.
5. Khan Z., Tiwari R.P., Khan N., Prasad G.B.K.S., Bisen P.S. Induction of apoptosis and sensitization of head and neck squamous carcinoma cells to cisplatin by targeting survivin gene expression. Curr. Gene Ther. 2012, 12:444-453.
6. Thomas G.C. Apoptosis and cancer: the genesis of a research field. Nat. Rev. Cancer 2009, 9:501-507.
7. Alenzi F.Q. Links between apoptosis, proliferation and the cell cycle. Br. J. Biomed. Sci. 2004, 61:99-102.
8. Cao L., Faha B., Dembski M., Tsai L.H., Harlow E., Dyson N. Independent binding of the retinoblastoma protein and p107 to the transcription factor E2F. Nature 1992, 355:176-179.
9. Ambrosone C.B., Curtis C., Harris C.C. The development of molecular epidemiology to elucidate cancer risk and prognosis: a historical perspective. Int. J. Mol. Epidemiol. Genet. 2010, 1:84-91.
10. Savelyeva L., Schwab M. Amplification of oncogenes revisited: from expression profiling to clinical application. Cancer Lett. 2001, 167:115-123.
11. Bishop M.I. Molecular themes in oncogenesis. Cell 1991, 64:235-248.
12. Jameson S.C. Maintaining the norm: T-cell homeostasis. Nat. Rev. Immunol. 2002, 2:547-556.
13. Jemal A.R., Siegel R., Ward E., Hao Y., Xu J., Thun M.J. Cancer statistics, 2009. CA Cancer J. Clin. 2009, 59:225-249.
14. Chiba I. Prevention of Betel Quid chewers' oral cancer in the Asian-Pacific area. Asian Pac. J. Cancer Prev. 2001, 2:263-269.
15. Stich H.F., Parida B.B., Brunnemann K.D. Localized formation of micronuclei in the oral mucosa and tobacco-specific nitrosamines in the saliva of "reverse" smokers, Khaini-tobacco chewers and gudakhu users. Int. J. Cancer 1992, 50:172-176.
16. Warnakulasuriya S., Johnson N.W., van der Waal I. Nomenclature and classification of potentially malignant disorders of the oral mucosa. J. Oral Pathol. Med. 2007, 36:575-580.
17. Tanaka T., Tanaka M., Tanaka T. Oral carcinogenesis and oral cancer chemoprevention: a review. Pathol. Res. Int. 2011, 1431246.
18. Martin L.M., Bouquot J.E., Wingo P.A., Heath C.W. Cancer prevention in the dental practice: oral cancer screening and tobacco cessation advice. J. Public Health Dent. 1996, 56:336-340.
19. Park N.H., Sapp J.P., Herbosa E.G. Oral cancer induced in hamsters with herpes simplex virus infection and simulated snuff-dipping. Oral Surg. Oral Med. Oral Pathol. 1996, 62:164-168.
20. Turati F., Garavello W., Tramacere I., Pelucchi C., Galeone C., Bagnardi V., Corrao G., Islami F., Fedirko V., Boffetta P., La Vecchia C., Negri E.A. Meta-analysis of alcohol drinking and oral and pharyngeal cancers: results from subgroup analyses. Alcohol Alcohol. 2013, 48:107-118.
21. Castellsagué X., Quintana M.J., Martínez M.C., Nieto A., Sánchez M.J., Juan A., Monner A., Carrera M., Agudo A., Quer M., Muñoz N., Herrero R., Franceschi S., Bosch F.X. The role of type of tobacco and type of alcoholic beverage in oral carcinogenesis. Int. J. Cancer 2004, 108:741-749.
22. zur Hausen H. Papillomavirus infections-a major cause of human cancers. Biochim. Biophys. Acta 1996, 1288:F55-F78.
23. D'Souzaa G., Dempseyb A. The role of HPV in head and neck cancer and review of the HPV Vaccine. Prev. Med. 2011, 53:S5-S11.
24. Smith E.M., Swarnavel S., Ritchie J.M., Wang D., Haugen T.H., Turek L.P. Prevalence of human papillomavirus in the oral cavity/oropharynx in a large population of children and adolescents. Pediatr. Infect. Dis. J. 2007, 26:836-840.
25. Kreimer A.R., Clifford G.M., Boyle P., Franceschi S. Human papillomavirus types in head and neck squamous cell carcinomas worldwide: a systematic review. Cancer Epidemiol. Biomarkers Prev. 2005, 14:467-475.
26. Syrjänen S. Viral infections in oral mucosa. Scand. J. Dent. Res. 1992, 100:17-31.
27. Scully C. Oncogenes, tumor suppressors and viruses in oral squamous carcinoma. J. Oral Pathol. Med. 1993, 22:337-347.
28. Franceschi S., Munoz N., Bosch X.F., Snijders P.J., Walboomers J.M. Human papillomavirus and cancers of the upper aerodigestive tract: a review of epidemiological and experimental evidence. Cancer Epidemiol. Biomarkers Prev. 1996, 5(1996):567-575.
29. Agrawal N., Frederick M.J., Pickering C.R., Bettegowda C., Chang K., Li R.J., Fakhry C., Xie T.X., Zhang J., Wang J., Zhang N., El-Naggar A.K., Jasser S.A., Weinstein J.N., Treviño L., Drummond J.A., Muzny D.M., Wu Y., Wood L.D., Hruban R.H., Westra W.H., Koch W.M., Califano J.A., Gibbs R.A., Sidransky D., Vogelstein B., Velculescu V.E., Papadopoulos N., Wheeler D.A., Kinzler K.W., Myers J.N. Exome sequencing of head and neck squamous cell carcinoma reveals inactivating mutations in NOTCH1. Science 2011, 26:1154-1157.
30. Stransky N., Egloff A.M., Tward A.D., Kostic A.D., Cibulskis K., Sivachenko A., Kryukov G.V., Lawrence M.S., Sougnez C., McKenna A., Shefler E., Ramos A.H., Stojanov P., Carter S.L., Voet D., Cortés M.L., Auclair D., Berger M.F., Saksena G., Guiducci C., Onofrio R.C., Parkin M., Romkes M., Weissfeld J.L., Seethala R.R., Wang L., Rangel-Escareño C., Fernandez-Lopez J.C., Hidalgo-Miranda A., Melendez-Zajgla J., Winckler W., Ardlie K., Gabriel S.B., Meyerson M., Lander E.S., Getz G., Golub T.R., Garraway L.A., Grandis J.R. The mutational landscape of head and neck squamous cell carcinoma. Science 2011, 26:1157-1160.
31. Schildt E.B., Eriksson M., Hardell L., Magnuson A. Oral infections and dental factors in relation to oral cancer: a Swedish case-control study. Eur. J. Cancer Prev. 1998, 7:201-206.
32. Kassim K.H., Daley T.D. Herpes simplex virus type 1 proteins in human oral squamous cell carcinoma. Oral Surg. Oral Med. Oral Pathol. 1998, 65:445-448.
33. Parker T.M., Smith E.M., Ritchie J.M., Haugen T.H., Vonka V., Turek L.P., Hamsikova E. Head and neck cancer associated with herpes simplex virus 1 and 2 and other risk factors. Oral Oncol. 2006, 42:288-296.
34. Starr J.R., Daling J.R., Fitzgibbons E.D., Madeleine M.M., Ashley R., Galloway D.A., Schwartz S.M. Serologic evidence of herpes simplex virus 1 infection and oropharyngeal cancer risk. Cancer Res. 2001, 61:8459-8464.
35. Atula T., Grenman R., Klemi P., Syrjanen S. Human papillomavirus, Epstein-Barr virus, human herpesvirus 8 and human cytomegalovirus involvement in salivary gland tumours. Oral Oncol. 1998, 34:391-395.
36. Al Moustafa A.E., Chen D., Ghabreau L., Akil N. Association between human papillomavirus and Epstein-Barr virus infections in human oral carcinogenesis. Med. Hypotheses 2009, 73:184-186.
37. Jalouli J., Jalouli M.M., Sapkota D., Ibrahim S.O., Larsson P.A., Sand L. Human papilloma virus, herpes simplex virus and epstein barr virus in oral squamous cell carcinoma from eight different countries. Anticancer Res. 2012, 32:571-580.
38. Polverini P.J., Nor J.E. Apoptosis and predisposition to oral cancer. CROBM 1999, 10:139-152.
39. Partridge M., Emilion G., Pateromichelakis S., Phillips E., Langdon J. Field cancerisation of the oral cavity: comparison of the spectrum of molecular alterations in cases presenting with both dysplastic and malignant lesions. Eur. J. Cancer B Oral Oncol. 1997, 33B:332-337.
40. Weber R.G., Scheer M., Born I.A., Joos S., Cobbers J.M., Hofele C., Reifenberger G., Zöller J.E., Lichter P. Recurrent chromosomal imbalances detected in biopsy material from oral premalignant and malignant lesions by combined tissue microdissection, universal DNA amplification, and comparative genomic hybridization. Am. J. Pathol. 1998, 153:295-303.
41. Ambatipudi S., Gerstung M., Gowda R., Pai P., Borges A.M., Schäffer A.A., Beerenwinkel N., Mahimkar M.B. Genomic profiling of advanced-stage oral cancers reveals chromosome 11q alterations as markers of poor clinical outcome. PLoS One 2011, 6:e17250.
42. Rosin M.P., Cheng X., Poh C., Lam W.L., Huang Y., Lovas J., Berean K., Epstein J.B., Priddy R., Le N.D., Zhang L. Use of allelic loss to predict malignant risk for low-grade oral epithelial dysplasia. Clin. Cancer Res. 2000, 6:357-362.
43. Reis P.P., Rogatto S.R., Kowalski L.P., Nishimoto I.N., Montovani J.C., Corpus G., Squire J.A., Kamel-Reid S. Quantitative real-time PCR identifies a critical region of deletion on 22q13 related to prognosis in oral cancer. Oncogene 2002, 21:6480-6487.
44. Bockmuhl U., Wolf G., Schmidt S., Schwendel A., Jahnke V., Dietel M., Petersen I. Genomic alterations associated with malignancy in head and neck cancer. Head Neck 1998, 20:145-151.
45. Oga A., Kong G., Tae K., Lee Y., Sasaki K. Comparative genomic hybridization analysis reveals 3q gain resulting in genetic alteration in 3q in advanced oral squamous cell carcinoma. Cancer Genet. Cytogenet. 2001, 127:24-29.
46. Hannahan D., Weinberger R.A. The hallmark of cancer. Cell 2000, 100:57-70.
47. Wong D.T., Gallagher G.T., Gertz R., Chang A.L.C., Shklar G. Transforming growth factor-α in chemically transformed hamster oral keratinocytes. Cancer Res. 1988, 48:3130-3134.
48. Nagatsuka H., Ishiwari Y., Tsujigiwa H., Nakano K., Nagai N. Quantitation of epidermal growth factor receptor gene amplification by competitive polymerase chain reaction in pre-malignant and malignant oral epithelial lesions. Oral Oncol. 2001, 37:599-604.
49. Wong D.T., Biswas D.K. Expression of c-erb B protooncogene during dimethylbenzanthracene induced tumorigenesis in hamster cheek pouch. Oncogene 1987, 2:67-72.
50. Pomerantz R.G., Grandis J.R. The epidermal growth factor receptor signaling network in head and neck carcinogenesis and implications for targeted therapy. Semin. Oncol. 2004, 31:734-743.
51. Sidransky D. Molecular genetics of head and neck cancer. Curr. Opin. Oncol. 1995, 7:229-233.
52. Lundberg A.S., Weinberg R.A. Control of the cell cycle and apoptosis. Eur. J. Cancer 1999, 35:1886-1894.
53. Koontongkaew S., Chareonkitkajorn L., Chanvitan A., Leelakriangsak M., Amornphimoltham P. Alterations of p53, pRb, cyclin D(1) and cdk4 in human oral and pharyngeal squamous cell carcinomas. Oral Oncol. 2000, 36:334-339.
54. Schliephake H. Prognostic relevance of molecular markers of oral cancer-a review. J. Oral Maxillofac. Surg. 2003, 32:233-245.
55. Teresa D.B., Neves K.A., Neto C.B., Fregonezi P.A., de Oliveira M.R., Zuanon J.A., Donadi E.A., Mendes-Junior C.T., Soares C.P. Computer-assisted analysis of cell proliferation markers in oral lesions. Acta Histochem. 2007, 109:377-387.
56. Khan Z., Tiwari R.P., Mulherkar R., Sah N.K., Prasad G.B.K.S., Shrivastava B.R., Bisen P.S. Detection of survivin and p53 in human oral cancer: correlation with clinicopathological findings. Head Neck 2009, 31:1039-1048.
57. Deyhimi P., Azmoudeh F. HSP27 and HSP70 expression in squamous cell carcinoma: an immunohistochemical study. Dent. Res. J. (Isfahan) 2012, 9:162-166.
58. Hayflick L. Mortality and immortality at the cellular level, a review. Biochemistry 1997, 62:1180-1190.
59. Yamazaki Y., Chiba I., Hirai A., Sugiura C., Notaniichi K., Kashiwazaki H., Tei K., Totsuka Y., Fukuda H. Specific p53 mutations predict poor prognosis in oral squamous cell carcinoma. Oral Oncol. 2003, 39:163-169.
60. Soni S., Kaur J., Kumar A., Chakravarti N., Mathur M., Bahadur S., Shukla N.K., Deo S.V., Ralhan R. Alterations of rb pathway components are frequent events in patients with oral epithelial dysplasia and predict clinical outcome in patients with squamous cell carcinoma. Oncology 2005, 68:314-325.
61. Flatharta C.O., Flint S., Toner M., Mabruk M. hTR RNA component as a marker of cellular proliferation in oral lichen planus. Asian Pac. J. Cancer Prev. 2008, 9:287-290.
62. Epstein J.B., Zhang L., Poh C., Nakamura H., Berean K., Rosin M.I. Increased allelic loss in toluidine blue-positive oral premalignant lesions. Oral Surg. Oral Med. Oral Pathol. Oral Radiol. Endod. 2003, 95:45-50.
63. Lingen M.W. Angiogenesis in the development of head and neck cancer and its inhibition by chemopreventive agents. Crit. Rev. Oral Biol. Med. 1999, 10:153-164.
64. Bancroft C.C., Chen Z., Dong G., Sunwoo J.B., Yeh N., Park C., Van Waes C. Coexpression of proangiogenic factors IL-8 and VEGF by human head and neck squamous cell carcinoma involves coactivation by MEK-MAPK and IKK-NF-kappaB signal pathways. Clin. Cancer Res. 2001, 7:435-442.
65. Khan Z., Khan N., Tiwari R.P., Sah N.K., Prasad G.B., Bisen P.S. Biology of Cox-2: an application in cancer therapeutics. Curr. Drug Targets 2011, 12:1082-1193.
66. Bánkfalvi A., Krabort M., Végh A., Felszeghy E., Piffkó J. Deranged expression of the E-cadherin/b-catenin complex and the epidermal growth factor receptor in the clinical evolution and progression of oral squamous cell carcinomas. J. Oral Pathol. Med. 2002, 31:450-457.
67. Behrens J., Mareel M.M., VanRoy F.M., Birchmeier W. Epithelial cells acquire invasive properties after the loss of uvomorulin-mediated cell-cell adhesion. J. Cell Biol. 1989, 113:173-185.
68. Kim M.S., Li S.L., Bertolami C.N., Cherrick H.M., Park N.H. State of p53, Rb and DCC tumor suppressor genes in human oral cancer cell lines. Anticancer Res. 1993, 13:1405-1413.
69. Harris C.C. Chemical and physical carcinogenesis; advances and perspectives for the 1990's. Cancer Ass. 1991, 51:5023-5044.
70. Murugan A.K., Munirajan A.K., Tsuchida N. Ras oncogenes in oral cancer: the past 20years. Oral Oncol. 2012, 48:383-392.
71. Barbacid M. Ras genes. Ann. Rev. Biochem. 1987, 56:776-827.
72. Downward J. Targeting RAS signalling pathways in cancer therapy. Nat. Rev. Cancer 2003, 3:11-22.
73. Avraham H., Park S.Y., Schinkmann K., Avraham S. RAFTK/Pyk2-mediated cellular signaling. Cell. Signal. 2000, 12:123-133.
74. Rajalingam K., Schreck R., Rapp U.R., Albert S. Ras oncogenes and their downstream targets. Biochim. Biophys. Acta 2007, 1773:1177-1195.
75. Karnoub A.E., Weinberg R.A. Ras oncogenes: split personalities. Nat. Rev. Mol. Cell Biol. 2008, 9:517-531.
76. Rogers C., Moukdar F., McGee M.A., Davis B., Buehrer B.M., Daniel K.W., Collins S., Barakat H., Robidoux J. EGF receptor (ERBB1) abundance in adipose tissue is reduced in insulin-resistant and type 2 diabetic women. J. Clin. Endocrinol. Metab. 2012, 97:329-340.
77. Miao B., Skidan I., Yang J., Lugovskoy A., Reibarkh M., Long K., Brazell T., Durugkar K.A., Maki J., Ramana C.V., Schaffhausen B., Wagner G., Torchilin V., Yuan J., Degterev A. Small molecule inhibition of phosphatidylinositol-3,4,5 triphosphate (PIP3) binding to pleckstrin homologydomains. Proc. Natl. Acad. Sci. U.S.A. 2010, 107:20126-20131.
78. Rodriguez-Viciana P., Warne P.H., Dhand R., Vanhaesebroeck B., Gout I., Fry M.J., Waterfield M.D., Downward J. Phosphatidylinositol-3-OH kinase as a direct target of Ras. Nature 1994, 370:527-532.
79. Neiman P.E., Elsaesser K., Loring G., Kimmel R. Myc oncogene-induced genomic instability: DNA palindromes in bursal lymphomagenesis. PLoS Genet. 2008, 4:e1000132.
80. Robson S.C., Ward L., Brown H., Turner H., Hunter E., Pelengaris S., Khan M. Deciphering c-MYC-regulated genes in two distinct tissues. BMC Genomics 2011, 12:476.
81. Evan G.T., Littlewood T. A matter of life and cell death. Science 1998, 281:1317-1322.
82. Massano J., Regateiro F.S., Januário G., Ferreira A. Oral squamous cell carcinoma: review of prognostic and predictive factors. Oral Surg. Oral Med. Oral Pathol. Oral Radiol. Endod. 2006, 102:67-76.
83. Spencer C.A., Groudine M. Control of c-myc regulation in normal and neoplastic cells. Adv. Cancer Res. 1991, 56:1-48.
84. Shachaf C.M., Gentles A.J., Elchuri S., Sahoo D., Soen Y., Sharpe O., Perez O.D., Chang M., Mitchel D., Robinson W.H., Dill D., Nolan G.P., Plevritis S.K., Fisher D.W. Genomic and proteomic analysis reveals a threshold level of MYC required for tumor maintenance. Cancer Res. 2008, 68:5132-5142.
85. Calado D.P., Sasaki Y., Godinho S.A., Pellerin A., Köchert K., Sleckman B.P., de Alborán I.M., Janz M., Rodig S., Rajewsky K. The cell-cycle regulator c-Myc is essential for the formation and maintenance of germinal centers. Nat. Immunol. 2012, 13:1092-1100.
86. de Alboran I.M., Oõhagan R.C., Gartner F., Malynn B., Davidson L., Rickert R., Rajewsky K., Depinho R.A., Alt F.W. Analysis of C-MYC function in normal cells via conditional gene-targeted mutation. Immunity 2001, 14:45-55.
87. Mateyak M.K., Obaya A.J., Adachi S., Sedivy J.M. Phenotypes of c-Myc-deficient rat fibroblasts isolated by targeted homologous recombination. Cell Growth Differ. 1997, 8:1039-1048.
88. Born T.L., Frost J.A., Schonthal A., Prendergast G.C., Feramisco J.R. c-Myc co-operates with activated Ras to induce the cdc2 promoter. Mol. Cell. Biol. 1994, 14:5710-5718.
89. Miyamoto R., Uzawa N., Nagaoka S., Hirata Y., Amagasa T. Prognostic significance of cyclin D1 amplification and overexpression in oral squamous cell carcinomas. Oral Oncol. 2003, 39:610-618.
90. Roussel M.F., Theodoras A.M., Pagano M., Sherr C.J. Rescue of defective mitogenic signaling by D-type cyclins. Proc. Natl. Acad. Sci. U.S.A. 1995, 92:6837-6841.
91. Daksis J.I., Lu R.Y., Facchini L.M., Marhin W.W., Penn L.J. Myc induces cyclin D1 expression in the absence of de novo protein synthesis and links mitogen-stimulated signal transduction to the cell cycle. Oncogene 1994, 9:3635-3645.
92. Simile M.M., De Miglio M.R., Muroni M.R., Frau M., Asara G., Serra S., Muntoni M.D., Seddaiu M.A., Daino L., Feo F., Pascale R.M. Down-regulation of c-myc and Cyclin D1 genes by antisense oligodeoxy nucleotides inhibits the expression of E2F1 and in vitro growth of HepG2 and Morris 5123 liver cancer cells 2004, 25:333-341.
93. Liao D.J., Thakur A., Wu J., Biliran H., Sarkar F.H. Perspectives on c-Myc, Cyclin D1, and their interaction in cancer formation, progression, and response to chemotherapy. Crit. Rev. Oncog. 2007, 13:93-158.
94. Jansen-Durr P., Meichle A., Steiner P., Pagano M., Finke D., Botz J., Wessbecher J., Draetta G., Eilers M. Differential modulation of cyclin gene expression by MYC. Proc. Natl. Acad. Sci. U.S.A. 1993, 90:3685-3689.
95. Hoang A.T., Cohen K.T., Barrett J.F., Bergstrom D.A., Dang C.V. Participation of cyclin A in Myc-induced apoptosis. Proc. Natl. Acad. Sci. U.S.A. 1994, 91:6875-6879.
96. Leone G., DeGregori J., Sears R., Jakoi L., Nevins J.R. Myc and Ras collaborate in inducing accumulation of active cyclin E/Cdk2 and E2F. Nature 1997, 387:422-426.
97. Galaktionov K., Chen X., Beach D. Cdc25 cell-cycle phosphatase as a target of c-myc. Nature 1996, 382:511-517.
98. Lu L.X., Domingo-Sananes M.R., Huzarska M., Novak B., Gould K.L. Multisite phosphoregulation of Cdc25 activity refines the mitotic entrance and exit switches. Proc. Natl. Acad. Sci. U.S.A. 2012, 109:9899-9904.
99. Grandori C., Cowley S.M., James L.P., Eisenman R.N. The Myc/Max/Mad network and the transcriptional control of cell behavior. Annu. Rev. Cell Dev. Biol. 2000, 16:653-699.
100. Packham G., Cleveland J.L. The role of ornithine decarboxylase in c-Myc-induced apoptosis. Curr. Top. Microbiol. Immunol. 1995, 194:283-290.
101. Hermeking H., Eick D. Mediation of c-Myc-induced apoptosis by p53. Science 1994, 265:2091-2093.
102. Land H., Parada L.F., Weinberg R.A. Tumorigenic conversion of primary embryo fibroblasts requires at least two cooperating oncogenes. Nature 1983, 304:596-602.
103. Zindy F., Eischen C.M., Randle D.H., Kamijo T., Cleveland J.L., Sherr C.J., Roussel M.F. Myc signaling via the ARF tumor suppressor regulates p53-dependent apoptosis and immortalization. Genes Dev. 1998, 12:2424-2433.
104. Pelengaris S., Khan M., Evan G. c-MYC: more than just a matter of life and death. Nat. Rev. Cancer 2002, 2:764-776.
105. Hsu B., Marin M.C., el Naggar A.K., Stephens L.C., Brisbay S., McDonnell T.J. Evidence that c-myc mediated apoptosis does not require wild-type p53 during lymphomagenesis. Oncogene 1995, 11:175-179.
106. Wang J.L., Xie Y., Allan S., Beach D., Hannon G.J. Myc activates telomerase. Genes Dev. 1998, 12:1769-1774.
107. Bissonnette R.P., Echeverri F., Mahboubi A., Green D.R. Apoptotic cell death induced by c-myc is inhibited by bcl-2. Nature 1992, 359:552-554.
108. Campone M., Noël B., Couriaud C., Grau M., Guillemin Y., Gautier F., Gouraud W., Charbonnel C., Campion L., Jézéquel P., Braun F., Barré B., Coqueret O., Barillé-Nion S., Juin P. c-Myc dependent expression of pro-apoptotic Bim renders HER2-overexpressing breast cancer cells dependent on anti-apoptotic Mcl-1. Mol. Cancer 2011, 10:110.
109. Soucie E.L., Annis M.G., Sedivy J., Filmus J., Leber B., Andrews D.W., Penn L.Z. Myc potentiates apoptosis by stimulating Bax activity at the mitochondria. Mol. Cell. Biol. 2001, 21:4725-4736.
110. Nesbit C.E., Tersak J.M., Grove L.E., Drzal A., Choi H., Prochownik E.V. Genetic dissection of c-myc apoptotic pathways. Oncogene 2000, 19:3200-3212.
111. Castellano E., Santos E. Functional specificity of ras isoforms: so similar but so different. Genes Cancer 2011, 2:216-231.
112. Wang M.L., Walsh R., Robinson K.L., Burchard J., Bartz S.R., Cleary M., Galloway D.A., Grandori C. Gene expression signature of c-MYC-immortalized human fibroblasts reveals loss of growth inhibitory response to TGFβ. Cell Cycle 2011, 10:2540-2548.
113. Misale S., Yaeger R., Hobor S., Scala E., Janakiraman M., Liska D., Valtorta E., Schiavo R., Buscarino M., Siravegna G., Bencardino K., Cercek A., Chen C.T., Veronese S., Zanon C., Sartore-Bianchi A., Gambacorta M., Gallicchio M., Vakiani E., Boscaro V., Medico E., Weiser M., Siena S., Di Nicolantonio F., Solit D., Bardelli A. Emergence of KRAS mutations and acquired resistance to anti-EGFR therapy in colorectal cancer. Nature 2012, 486:532-536.
114. Tadokoro K., Ueda M., Ohshima T., Fujita K., Rikimaru K., Takahashi N., Enomoto S., Tuchida N. Activation of oncogenes in human oral cancer cells: a novel codon 13 mutation of c-H-ras-1 and concurrent amplifications of c-erbB-1 and c-myc. Oncogene 1989, 4:499-505.
115. Davies H., Bignell G.R., Cox C., Stephens P., Edkins S., Clegg S., Teague J., Woffendin H., Garnett M.J., Bottomley W., Davis N., Dicks E., Ewing R., Floyd Y., Gray K., Hall S., Hawes R., Hughes J., Kosmidou V., Menzies A., Mould C., Parker A., Stevens C., Watt S., Hooper S., Wilson R., Jayatilake H., Gusterson B.A., Cooper C., Shipley J., Hargrave D., Pritchard-Jones K., Maitland N., Chenevix-Trench G., Riggins G.J., Bigner D.D., Palmieri G., Cossu A., Flanagan A., Nicholson A., Ho J.W., Leung S.Y., Yuen S.T., Weber B.L., Seigler H.F., Darrow T.L., Paterson H., Marais R., Marshall C.J., Wooster R., Stratton M.R., Futreal P.A. Mutations of the BRAF gene in human cancer. Nature 2002, 417:949-954.
116. Rodenhuis S. Ras and human tumors. Semin. Cancer Biol. 1992, 3:241-247.
117. Mitelman F. Recurrent chromosome aberrations in cancer. Mutat. Res. 2000, 462:247-253.
118. Tomlins S.A., Rhodes D.R., Perner S., Dhanasekaran S.M., Mehra R., Sun X.W., Varambally S., Cao X., Tchinda J., Kuefer R., Lee C., Montie J.E., Shah R.B., Pienta K.J., Rubin M.A., Chinnaiyan A.M. Recurrent fusion of TMPRSS2 and ETS transcription factor genes in prostate cancer. Science 2005, 310:644-648.
119. Gorgoulis V.G., Vassiliou L.V.F., Karakaidos P., Zacharatos P., Kotsinas A., Liloglou T., Venere M., Ditullio R.A., Kastrinakis N.G., Levy B., Kletsas D., Yoneta A., Herlyn M., Kittas C., Halazonetis T.D. Activation of the DNA damage checkpoint and genomic instability in human precancerous lesions. Nature 2005, 434:907-913.
120. Smeets S.J., van der Plas M., Schaaij-Visser T.B., van Veen E.A., van Meerloo J., Braakhuis B.J., Steenbergen R.D., Brakenhoff R.H. Immortalization of oral keratinocytes by functional inactivation of the p53 and pRb pathways. Int. J. Cancer 2011, 128:1596-1605.
121. Kerdpon D., Rich A.M., Reade P.C. Expression of p53 in oral mucosal hyperplasia, dysplasia and squamous cell carcinoma. Oral Dis. 1997, 3:86-92.
122. Alsner J., Sørensen S.B., Overgaard J. TP53 mutation is related to poor prognosis after radiotherapy, but not surgery, in squamous cell carcinoma of the head and neck. Radiother. Oncol. 2001, 59:179-185.
123. Khan Z., Khan N., Tiwari R.P., Patro I.K., Prasad G.B.K.S., Bisen P.S. Downregulation of survivin by oxaliplatin diminishes radioresistance of head and neck squamous carcinoma cells. Radiother. Oncol. 2010, 96:267-273.
124. Khan Z., Bhadouria P., Gupta R., Bisen P.S. Tumor control by manipulation of the human anti-apoptotic survivin gene. Curr. Cancer Ther. Rev. 2006, 2:73-79.
125. Lane D.P. p53, Guardian of the genome. Nature 1992, 358:15-16.
126. Jakus J., Yeudall W.A. Growth inhibitory concentrations of EGF induce p21 (WAFI/Cipl) and alter cell cycle control in squamous carcinoma cells. Oncogene 1996, 12:2369-2376.
127. Buchkovich K., Duffy L.A., Harlow E. The retinoblastoma protein is phosphorylated during specific phases of the cell cycle. Cell 1989, 58:1097-1105.
128. Vazquez A., Bond E.E., Levine A.J., Bond G.L. The genetics of the p53 pathway, apoptosis and cancer therapy. Nat. Rev. Drug Discov. 2008, 7:979-987.
129. Polyak K., Xia Y., Zweier J.L., Kinzler K.W., Vogelstein B. A model for p53-induced apoptosis. Nature 1997, 389:300-305.
130. Wilson J.W., Pritchard D.M., Hickman J.A., Potten C.S. Radiation-induced p53 and p21WAF-1/CIP1 expression in the murine intestinal epithelium: apoptosis and cell cycle arrest. Am. J. Pathol. 1998, 153:899-909.
131. Yang A., Kaghad M., Caput D., McKeon F. On the shoulders of giants: p63, p73 and the rise of p53. Trends Genet. 2002, 18:90-95.
132. Dick F.A. Structure-function analysis of the retinoblastoma tumor suppressor protein-is the whole a sum of its parts?. Cell Div 2007, 2:26.
133. Pande P., Mathur M., Shukla N.K., Ralhan R. pRb and p16 protein alterations in human oral tumorigenesis. Oral Oncol. 1998, 34:396-403.
134. Wu C.L., Roz L., McKown S., Sloan P., Read A.P., Holland S., Porter S., Scully C., Paterson I., Tavassoli M., Thakker N. DNA studies underestimate the major role of CDKN2A inactivation in oral and oropharyngeal squamous cell carcinomas. Genes Chromosomes Cancer 1999, 25:16-25.
135. Shintani S., Nakahara Y., Mihara M., Ueyama Y., Matsumura T. Inactivation of the p14(ARF), p15(INK4B) and p16(INK4A) genes is a frequent event in human oral squamous cell carcinomas. Oral Oncol. 2001, 37:498-504.
136. Enoch T., Norbury C. Cellular responses to DNA damage: cell cycle checkpoints, apoptosis and the role of p53 and AMT. Trends Biochem. Sci. 1995, 20:426-430.
137. Wang S., Ghosh R.N., Chellappan S.P. Raf-1 physically interacts with Rb and regulates its function: a link between mitogenic signaling and cell cycle regulation. Mol. Cell. Biol. 1998, 18:7487-7489.
138. Macleod K.F., Hu Y., Jacks T. Loss of Rb activates both p53-dependent and independent cell death pathways in the developing mouse nervous system. EMBO J. 1996, 15:6178-6188.
139. Hsieh J.K., Yap D., O'Connor D.J., Fogal V., Fallis L., Chan F., Zhong S., Lu X. Novel function of the cyclin A binding site of E2F in regulating p53-induced apoptosis in response to DNA damage. Mol. Cell. Biol. 2002, 22:78-93.
140. Decary S., Decesse J.T., Ogryzko V., Reed J.C., Naguibneva I., Harel-Bellan A., Cremisi C.E. The retinoblastoma protein binds the promoter of the survival gene bcl-2 and regulates its transcription in epithelial cells through transcription factor AP-2. Mol. Cell. Biol. 2002, 22:7877-7888.
141. Blattner C., Sparks A., Lane D. Transcription factor E2F-1 is upregulated in response to DNA damage in a manner analogous to that of p53. Mol. Cell. Biol. 1999, 19:3704-3713.
142. Moroni M.C., Hickman E.S., Denchi E.L., Caprara G., Colli E., Cecconi F., Muller H., Helin K. Apaf-1 is a transcriptional target for E2F and p53. Nat. Cell Biol. 2001, 3:552-558.
143. Munro S., Carr S.M., La Thangue N.B. Diversity within the pRb pathway: is there a code of conduct?. Oncogene 2012, 31:4343-4352.
144. Hiebert S.W., Packham G., Strom D.K., Haffner R., Oren M., Zambetti G., Cleveland J.L. E2F-1: DP-1 induces p53 and overrides survival factors to trigger apoptosis. Mol. Cell. Biol. 1995, 15:6864-6874.
145. Tsujimoto Y., Cossman J., Jaffe E., Croce C.M. Involvement of the bcl-2 gene in human follicular lymphoma. Science 1985, 228:1440-1443.
146. Frenzel A., Grespi F., Chmelewskij W., Villunger A. Bcl2 family proteins in carcinogenesis and the treatment of cancer. Apoptosis 2009, 14:584-596.
147. Camisasca D.R., Honorato J., Bernardo V., da Silva L.E., da Fonseca E.C., de Faria P.A., Dias F.L., Lourenço Sde Q. Expression of Bcl-2 family proteins and associated clinicopathologic factors predict survival outcome in patients with oral squamous cell carcinoma. Oral Oncol. 2009, 45:225-233.
148. Coutinho-Camillo C.M., Lourenço S.V., Nishimoto I.N., Kowalski L.P., Soares F.A. Expression of Bcl2 family proteins and association with clinicopathological characteristics oforal squamous cellcarcinoma. Histopathology 2010, 57:304-316.
149. Ribeiro D.A., Salvadori D.M., Marques M.E. Abnormal expression of bcl-2 and bax in rat tongue mucosa during the development of squamous cell carcinoma induced by 4-nitroquinoline 1-oxide. Int. J. Exp. Pathol. 2005, 86:375-381.
150. Kang M.H., Reynolds C.P. Bcl-2 inhibitors: targeting mitochondrial apoptotic pathways in cancer therapy. Clin. Cancer Res. 2009, 15:1126-1132.
151. Oltvai Z.N., Milliman C.L., Korsmeyer S.J. Bcl-2 heterodimerizes in vivo with a conserved homolog, Bax, that accelerates programmed cell death. Cell 1993, 74:609-619.
152. Huang D.C.S., Cory S., Strasser A. Bcl-2, Bcl-XL and adenovirus protein E1B19kD are functionally equivalent in their ability to inhibit cell death. Oncogene 1997, 14:405-414.
153. Suzuki M., Youle R.J., Tjandra N. Structure of Bax: coregulation of dimer formation and intracellular localization. Cell 2000, 103:645-654.
154. Desagher S., Osen-Sand A., Nichols A., Eskes R., Montessuit S., Lauper S., Maundrell K., Antonsson B., Martinou J.C. Bid-induced conformational change of Bax is responsiblefor mitochondrial cytochrome-c release during apoptosis. J. Cell Biol. 1999, 144:891-901.
155. Griffiths G.J., Dubrez L., Morgan C.P., Jones N.A., Whitehouse J., Corfe B.M., Dive C., Hickman J.A. Cell damage-induced conformational changes of the pro-apoptotic protein Bak in vivo precede the onset of apoptosis. J. Cell Biol. 1999, 144:903-914.
156. Parsons M.J., Green D.R. Mitochondria in cell death. Essays Biochem. 2010, 47:99-111.
157. Puthalakath H., Strasser A. Keeping killers on a tight leash: transcriptional and post-translational control of the pro-apoptotic activity of BH3-only proteins. Cell Death Diff. 2002, 9:505-512.
158. Cheng E.H., Wei M.C., Weiler S., Flavell R.A., Mak T.W., Lindsten T., Korsmeyer S.J. BCL-2, BCL-X(L) sequester BH3 domain-only molecules preventing BAX- and BAK-mediated mitochondrial apoptosis. Mol. Cell 2001, 8:705-711.
159. Llambi F., Green D.R. Apoptosis and oncogenesis: give and take in the BCL-2 family. Curr. Opin. Genet. Dev. 2011, 21:12-20.
160. Yin X.M., Oltvai Z.N., Korsmeyer S.J. Heterodimerization with Bax is required for Bcl-2 to repress cell death. Curr. Top. Microbiol. Immunol. 1995, 194:331-338.
161. Kinoshita T., Yokota T., Arai K., Miyajima A. Regulation of Bcl-2 expression by oncogenic Ras protein in hematopoietic cells. Oncogene 1995, 10:2207-2212.
162. Yamamoto K., Ichijo H., Korsmeyer S.J. Bcl-2 is phosphorylated and inactivated by an ASK1/Jun N-terminal protein kinase pathway normally activated at G2/M. Mol. Cell. Biol. 1999, 19:8469-8478.
163. Haldar S., Chintapalli J., Croce C.M. Taxol induced Bcl-2 phosphorylation and death of prostate cancer cells. Cancer Res. 1996, 56:1253-1255.
164. Furukawa Y., Iwase S., Kikuchi J., Terui Y., Nakamura M., Yamada H., Kano Y., Matsuda M. Phosphorylation of Bcl-2 protein by CDC2 kinase during G2/M phases and its role in cell cycle regulation. J. Biol. Chem. 2000, 275:21661-21667.
165. Maundrell K., Antonsson B., Magnenat E., Camps M., Muda M., Chabert C., Gillieron C., Boschert U., Vial-Knecht E., Martinou J.C., Arkinstall S. Bcl-2 undergoes phosphorylation by c-Jun N-terminal kinase/stress-activated protein kinases in the presence of the constitutively active GTP-binding protein Rac1. J. Biol. Chem. 1997, 272:25238-25342.
166. Nagata S. Fas ligand-induced apoptosis. Annu. Rev. Genet. 1999, 33:29-55.
167. Das S.N., Khare P., Singh M.K., Sharma S.C. Fas receptor (CD95) & Fas ligand (CD178) expression in patients with tobacco-related intraoral squamous cell carcinoma. Indian J. Med. Res. 2011, 134:54-60.
168. Tanaka M., Itai T., Adachi M., Nagata S. Downregulation of Fas ligand by shedding. Nat. Med. 1998, 4:31-36.
169. Strand S., Hofmann W.J., Hug H., Müller M., Otto G., Strand D., Mariani S.M., Stremmel W., Krammer P.H., Galle P.R. Lymphocyte apoptosis induced by CD95 (APO-1/Fas) ligand-expressing tumor cells-a mechanism of immune evasion?. Nat. Med. 1996, 2:1361-1366.
170. Abrahams V.M., Kamsteeg M., Mor G. The Fas/Fas ligand system and cancer: immune privilege and apoptosis. Mol. Biotechnol. 2003, 25:19-30.
171. Fukazawa T., Fujiwara T., Morimoto Y., Shao J., Nishizaki M., Kadowaki Y., Hizuta A., Owen-Schaub L.B., Roth J.A., Tanaka N. Differential involvement of the CD95 (Fas/APO-1) receptor/ligand system on apoptosis induced by the wild-type p53 gene transfer in human cancer cells. Oncogene 1999, 18:2189-2199.
172. Owen-Schaub L.B., Radinsky R., Kruzel E., Berry K., Yonehara S. Anti-Fas on nonhematopoietic tumors: levels of Fas/APO-1 and bcl- 2 are not predictive of biological responsiveness. Cancer Res. 1994, 54:1580-1586.
173. Chinnaiyan A.M., O'Rourke K., Tewari M., Dixit V.M. FADD, a novel death domain containing protein, interacts with the death domain of Fas and initiates apoptosis. Cell 1995, 81:505-512.
174. Duan H., Dixit V.M. RAIDD is a new 'death' adaptor molecule. Nature 1997, 385:86-89.
175. Yang X., Khosravi-Far R., Chang H.Y., Baltimore D. Daxx, a novel Fas-binding protein that activates JNK and apoptosis. Cell 1997, 89:1067-1076.
176. Faris M., Latinis K.M., Kempiak S.J., Koretzky G.A., Nel A. Stress induced Fas ligand expression in T cells is mediated through a MEK kinase 1-regulated response element in the Fas ligand promoter. Mol. Cell. Biol. 1998, 18:5414-5424.
177. Kasibhatla S., Brunner T., Genestier L., Echeverri F., Mahboubi A. Green DR, DNA damaging agents induce expression of Fas ligand and subsequent apoptosis in T lymphocytes via the activation of NF-kB and AP-1. Mol. Cell 1998, 1:543-551.
178. Miyashita T., Mami U., Inoue T., Reed J.C., Yamada M. Bcl-2 relieves the trans-repressive function of the glucocorticoid receptor and inhibits the activation of CPP32-like cysteine proteases. Biochem. Biophys. Res. Commun. 1997, 233:781-787.
179. Krueger A., Schmitz I., Baumann S., Krammer P.H., Kirchhoff S. Cellular FLICE-inhibitory protein splice variants inhibit different steps of caspase-8 activation at the CD95 death-inducing signaling complex. J. Biol. Chem. 2001, 276:20633-20640.
180. Cao X., Pobezinskaya Y.L., Morgan M.J., Liu Z.G. The role of TRADD in TRAIL-induced apoptosis and signalling. FASEB J. 2011, 25:1353-1358.
181. Picarda G., Trichet V., Téletchéa S., Heymann D., Rédini F. TRAIL receptor signaling and therapeutic option in bone tumors: the trap of the bone microenvironment. Am. J. Cancer Res. 2012, 2:45-64.
182. Pan G., Ni J., Wei Y.F., Yu G., Gentz R., Dixit V.M. An antagonist decoy receptor and a death domain-containing receptor for TRAIL. Science 1997, 277:815-818.
183. Falschlehner C., Emmerich C.H., Gerlach B., Walczak H. TRAIL signalling: decisions between life and death. Int. J. Biochem. Cell Biol. 2007, 39:1462-1475.
184. Zhang X.D., Borrow J.M., Zhang X.Y., Nguyen T., Hersey P. Activation of ERK1/2 protects melanoma cells from TRAIL-induced apoptosis by inhibiting Smac/DIABLO release from mitochondria. Oncogene 2003, 22:2869-2881.
185. Baader E., Toloczko A., Fuchs U., Schmid I., Beltinger C., Ehrhardt H., Debatin K.M., Jeremias I. Tumor necrosis factor-related apoptosis-inducing ligand-mediated proliferation of tumor cells with receptor-proximal apoptosis defects. Cancer Res. 2005, 65:7888-7895.
186. Johnstone R.W., Frew A.J., Smyth M.J. The TRAIL apoptotic pathway in cancer onset, progression and therapy. Nat. Rev. Cancer 2008, 8:782-798.
187. Grunert M., Gottschalk K., Kapahnke J., Gündisch S., Kieser A., Jeremias I. The adaptor protein FADD and the initiator caspase-8 mediate activation of NF-κB by TRAIL. Cell Death Dis. 2012, 3:e414.
188. Li H., Lin X. Positive and negative signalling components involved in TNFalpha-induced NFkappaB activation. Cytokine 2008, 41:1-8.
189. Ehrhardt H., Fulda S., Schmid I., Hiscott J., Debatin K.M., Jeremias I. TRAIL induced survival and proliferation in cancer cells resistant towards TRAIL-induced apoptosis mediated by NF-kappaB. Oncogene 2003, 22:3842-3852.
190. Malinin N.L., Boldin M.P., Kovalenko A.V., Wallach D. MAP3K-related kinase involved in NF-kappaB induction by TNF, CD95 and IL-1. Nature 1997, 385:540-544.
191. Kim J.Y., Lee J.Y., Kim D.G., Koo G.B., Yu J.W., Kim Y.S. TRADD is critical for resistance to TRAIL-induced cell death through NF-κB activation. FEBS Lett. 2011, 585:2144-2150.
192. Devin A., Cook A., Lin Y., Rodriguez Y., Kelliher M., Liu Z. The distinct roles of TRAF2 and RIP in IKK activation by TNF-R1: TRAF2 recruits IKK to TNF-R1 while RIP mediates IKK activation. Immunity 2000, 12:419-429.
193. Hu W.H., Johnson H., Shu H.B. Tumor necrosis factorrelated apoptosis-inducing ligand receptors signal NF-kappaB and JNK activation and apoptosis through distinct pathways. J. Biol. Chem. 1999, 274:30603-30610.
194. Lin Y., Devin A., Cook A., Keane M.M., Kelliher M., Lipkowitz S., Liu Z.G. The death domain kinase RIP is essential forTRAIL(Apo2L)-induced activation of IkappaB kinase and c-Jun N-terminal kinase. Mol. Cell. Biol. 2000, 20:6638-6645.
195. Wajant H. TRAIL and NFkappaB signalling-a complex relationship. Vitam. Horm. 2004, 67:101-132.
196. Lin Y., Devin A., Rodriguez Y., Liu Z.G. Cleavage of the death domain kinase RIP by caspase-8 prompts TNF-induced apoptosis. Genes Dev. 1999, 13:2514-2526.
197. Martinon F., Holler N., Richard C., Tschopp J. Activation of a pro-apoptotic amplification loop through inhibition of NF-kappaB-dependent survival signals by caspase-mediated inactivation of RIP. FEBS Lett. 2000, 468:134-136.
198. Chen X., Kandasamy K., Srivastava R.K. Differential roles of RelA (p65) and c-Rel subunits of nuclear factor κB in tumor necrosis factor-related apoptosis-inducing ligand signalling. Cancer Res. 2003, 63:1059-1066.
199. Ganten T.M., Koschny R., Haas T.L., Sykora J., Li-Weber M., Herzer K., Walczak H. Proteasome inhibition sensitizes hepatocellular carcinoma cells, but not human hepatocytes, to TRAIL. Hepatology 2005, 42:588-597.
200. Ishimura N., Isomoto H., Bronk S.F., Gores G.J. Trail induces cell migration and invasion in apoptosis-resistant cholangiocarcinoma cells. Am. J. Physiol. Gastrointest. Liver Physiol. 2006, 290:129-136.
201. Kaltschmidt B., Kaltschmidt C., Hofmann T.G., Hehner S.P., Droge W., Schmitz M.L. The pro- or antiapoptotic function of NF-kappaB is determined by the nature of the apoptotic stimulus. Eur. J. Biochem. 2000, 267:3828-3835.
202. Kuhnel F., Zender L., Paul Y., Tietze M.K., Trautwein C., Manns M., Kubicka S. NFkappaB mediates apoptosis through transcriptional activation of Fas (CD95) in adenoviral hepatitis. J. Biol. Chem. 2000, 275:6421-6427.
203. Glasgow J.N., Qiu J., Rassin D., Grafe M., Wood T., Perez-Pol J.R. Transcriptional regulation of the Bcl-X gene by NF-kappaB is an element of hypoxic responses in the rat brain. Neurochem. Res. 2001, 26:647-659.
204. Karin M. NF-kappaB as a critical link between inflammation and cancer. Cold Spring Harb. Perspect. Biol. 2009, 1:a000141.
205. Sah N.K., Munshi A., Kurland J.F., McDonnell T.J., Su B., Meyn R.E. Translation inhibitors sensitize prostate cancer cells to apoptosis induced by tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) by activating c-Jun N-terminal kinase. J. Biol. Chem. 2003, 278:20593-20602.
206. Weldon C.B., Parker A.P., Patten D., Elliott S., Tang Y., Frigo D.E., Dugan C.M., Coakley E.L., Butler N.N., Clayton J.L., Alam J., Curiel T.J., Beckman B.S., Jaffe B.M., Burow M.E. Sensitization of apoptoticallyresistant breast carcinoma cells to TNF and TRAIL by inhibition of p38 mitogen-activated protein kinase signalling. Int. J. Oncol. 2004, 24:1473-1480.
207. Frese S., Pirnia F., Miescher D., Krajewski S., Borner M.M., Reed J.C., Schmid R.A. PG490-mediated sensitization of lung cancer cells to Apo2L/TRAIL-induced apoptosis requires activation of ERK2. Oncogene 2003, 22:5427-5435.
208. Ohtsuka T., Buchsbaum D., Oliver P., Makhija S., Kimberly R., Zhou T. Synergistic induction of tumor cell apoptosis by death receptor antibody and chemotherapy agent through JNK/p38 and mitochondrial death pathway. Oncogene 2003, 22:2034-2044.
209. Kimberley F.C., Screaton G.R. Following a TRAIL: update on a ligand and its five receptors. Cell Res. 2004, 14:359-372.
210. Thayaparasingham B., Kunz A., Peters N., Kulms D. Sensitization of melanoma cells to TRAIL by UVB-induced and NF-kappaB-mediated downregulation of xIAP. Oncogene 2009, 28:345-362.
211. Snell V., Clodi K., Zhao S., Goodwin R., Thomas E.K., Morris S.W., Kadin M.E., Cabanillas F., Andreeff M., Younes A. Activity of TNF-related apoptosis-inducing ligand (TRAIL) in haematological malignancies. Br. J. Haematol. 1997, 99:618-624.
212. Andreeff M., Wong G., Koziner B., Espiritu E., Clarkson B. Non B-Non T acute lymphoblastic leukemia (ALL): evidence for complete b cell differentiation of a quiescent subpopulation and their response to induction therapy. Proc. Am. Assoc. Cancer Res. 1985, 26:111.
213. Vigneswaran N., Baucum D.C., Wu J., Lou Y., Bouquot J., Muller S., Zacharias W. Repression of tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) but not its receptors during oral cancer progression. BMC Cancer 2007, 25:108.
214. Teng M.S., Brandwein-Gensler M.S., Teixeira M.S., Martignetti J.A., Duffey D.C. A study of TRAIL receptors in squamous cell carcinoma of the head and neck. Arch. Otolaryngol. Head Neck Surg. 2005, 131:407-412.
215. Finnberg N., El-Deiry W.S. Selective TRAIL-induced apoptosis in dysplastic neoplasia of the colon may lead to new neoadjuvant or adjuvant therapies. Clin. Cancer Res. 2006, 12:4132-4136.
216. Lu X., Arbiser J.L., West J., Hoedt-Miller M., Sheridan A., Govindarajan B., Harral J.W., Rodman D.M., Fouty B. Tumor necrosis factor-related apoptosis-inducing ligand can induce apoptosis in subsets of premalignant cells. Am. J. Pathol. 2004, 165:1613-1620.
217. Pindborg J.J., Reichart P.A., Smith C.J., der W.J. Histological Typing of Cancer and Precancer of the Oral Mucosa WHO 1997, Springer, New York. 2nd ed.
218. Strater J., Hinz U., Walczak H., Mechtersheimer G., Koretz K., Herfarth C., Moller P., Lehnert T. Expression of TRAIL and TRAIL receptors in colon carcinoma: TRAIL-R1 is an independent prognostic parameter. Clin. Cancer Res. 2002, 8:3734-3740.
219. Stander S., Schwarz T. Tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) is expressed in normal skin and cutaneous inflammatory diseases, but not in chronically UV-exposed skin and non-melanoma skin cancer. Am. J. Dermatopathol. 2005, 27:116-121.
220. Yoldas B., Ozer C., Ozen O., Canpolat T., Dogan I., Griffith T.S., Sanlioglu S., Ozluoglu L.N. Clinical significance of TRAIL and TRAIL receptors in patients with head and neck cancer. Head Neck 2011, 33:1278-1284.
221. Yagita H., Takeda K., Hayakawa Y., Smyth M.J., Okumura K. TRAIL and its receptors as targets for cancer therapy. Cancer Sci. 2004, 95:777-783.
222. Wang Q., Wang X., Hernandez A., Hellmich M.R., Gatalica Z., Evers B.M. Regulation of TRAIL expression by the phosphatidylinositol 3-kinase/Akt/GSK-3 pathway in human colon cancer cells. J. Biol. Chem. 2002, 277:36602-36610.
223. Kalyankrishna S., Grandis J.R. Epidermal growth factor receptor biology in head and neck cancer. J. Clin. Oncol. 2006, 24:2666-2672.
224. Lazarus P., Sheikh S.N., Ren Q., Schantz S.P., Stern J.C., Richie J.P., Jr J.Y. Park, p53, but not p16 mutations in oral squamous cell carcinomas are associated with specific CYP1A1 and GSTM1 polymorphic genotypes and patient tobacco use. Carcinogenesis 1998, 19:509-514.
225. El-Deiry W.S. Insights into cancer therapeutic design based on p53 and TRAIL receptor signaling. Cell Death Differ. 2001, 8:1066-1075.
226. Chowdhury I., Tharakan B., Bhat G.K. Caspases - an update. Comp. Biochem. Physiol. B Biochem. Mol. Biol. 2008, 151:10-27.
227. Hofmann K., Bucher P., Tschopp J. The CARD domain: a new apoptotic signalling motif. Trends Biochem. Sci. 1997, 22:155-156.
228. Chou J.J., Matsuo H., Duan H., Wagner G. Solution structure of the RAIDD CARD and model for CARD/CARD interaction in caspase-2 and caspase-9 recruitment. Cell 1998, 94:171-180.
229. Callus B.A., Vaux D.L. Caspase inhibitors: viral, cellular and chemical. Cell Death Differ. 2007, 14:73-78.
230. Brand I.L., Green M.M., Civciristov S., Pantaki-Eimany D., George C., Gort T.R., Huang N., Clem R.J., Hawkins C.J. Functional and biochemical characterization of the baculovirus caspase inhibitor MaviP35. Cell Death Dis. 2011, 2:e242.
231. Zhou Q., Krebs J.F., Snipas S.J., Price A., Alnemri E.S., Tomaselli K.J., Salvesen G.S. Interaction of the baculovirus anti-apoptotic protein p35 with caspases - specificity, kinetics, and characterization of the caspase/p35 complex. Biochemistry 1998, 37:10757-10765.
232. Fulda S. Inhibitor of apoptosis (IAP) proteins: novel insights into the cancer-relevant targets for cell death induction. ACS Chem. Biol. 2009, 4:499-501.
233. Deveraux Q.L., Roy N., Stennicke H.R., Van Arsdale T., Zhou Q., Srinivasula S.M., Alnemri E.S., Salvesen G.S., Reed J.C. IAPs block apoptotic events induced by caspase-8 and cytochrome c by direct inhibition of distinct caspases. EMBO J. 1998, 17:2215-2223.
234. Damgaard R.B., Gyrd-Hansen M. Inhibitor of Apoptosis (IAP) Proteins in Regulation of Inflammation and Innate Immunity. Discov. Med. 2011, 11:221-231.
235. Roy N., Mahadevan M.S., McLean M., Shutler G., Yaraghi Z., Farahani R., Baird S., Besner-Johnston A., Lefebvre C., Kang X. The gene for neuronal apoptosis inhibitory protein is partially deleted in individuals with spinal muscular atrophy. Cell 1995, 80:167-178.
236. Dierlamm J., Baens M., Wlodarska I., Stefanova-Ouzounova M., Hernandez J.M., Hossfeld D.K., De Wolf-Peeters C., Hagemeijer A., Van den Berghe H., Marynen P. The apoptosis inhibitor gene API2 and a novel 18q gene, MLT, are recurrently rearranged in the t(11;18)(q21;q21)p6ssociated with mucosa-associated lymphoid tissue lymphomas. Blood 1999, 93:3601-3609.
237. Tamm I., Wang Y., Sausville E., Scudiero D.A., Vigna N., Oltersdorf T., Reed J.C. IAP-family protein survivin inhibits caspase activity and apoptosis induced by Fas (CD95), Bax, caspases, and anticancer drugs. Cancer Res. 1998, 58:5315-5320.
238. Adida C., Berrebi D., Peuchmaur M., Reyes-Mugica M., Altieri D.C. Anti-apoptosis gene, survivin, and prognosis of neuroblastoma. Lancet 1998, 351:882-883.
239. Lu C.D., Altieri D.C., Tanigawa N. Expression of a novel antiapoptosis gene, survivin, correlated with tumor cell apoptosis and p53 accumulation in gastric carcinomas. Cancer Res. 1998, 58:1808-1812.
240. Kawasaki H., Altieri D.C., Lu C.D., Toyoda M., Tenjo T., Tanigawa N. Inhibition of apoptosis by survivin predicts shorter survival rates in colorectal cancer. Cancer Res. 1998, 58:5071-5074.
241. Altieri D.C. Xa receptor EPR-1. FASEB J. 1995, 9:860-865.
242. Adida C., Crotty P.L., McGrath J., Berrebi D., Diebold J., Altieri D.C. Developmentally regulated expression of the novel cancer anti-apoptosis gene survivin in human and mouse differentiation. Am. J. Pathol. 1998, 152:43-49.
243. Goerner M., Seiwert T.Y., Sudhoff H. Molecular targeted therapies in head and neck cancer - An update of recent developments. Head Neck Oncol. 2010, 2:8.
244. Stewart J.S., Cohen E.E., Licitra L., van Herpen C.M., Khorprasert C., Soulieres D., Vodvarka P., Rischin D., Garin A.M., Hirsch F.R., Varella-Garcia M., Ghiorghiu S., Hargreaves L., Armour A., Speake A., Swaisland A., Vokes E.E. Phase III study of gefitinib compared with intravenous methotrexate for recurrent squamous cell carcinoma of the head and neck. J. Clin. Oncol. 2009, 11:1864-1871.
245. Lewis N., Marshall J., Amelsberg A., Cohen R., Stopfer P., Hwang J., Malik S. A phase I dose escalation study of BIBW 2992, an irreversible dual EGFR/HER2 receptor tyrosine kinase inhibitor, in a 3 week on 1 week off schedule in patients with advanced solid tumors. J. Clin. Oncol. 2006, 24:2449s.
246. Rusnak D.W., Lackey K., Affleck K., Wood E.R., Alligood K.J., Rhodes N., Keith B.R., Murray D.M., Knight W.B., Mullin R.J., Gilmer T.M. The effects of the novel, reversible epidermal growth factor receptor/ErbB-2 tyrosine kinase inhibitor, GW2016, on the growth of human normal and tumor-derived cell lines in vitro and in vivo. Mol. Cancer Ther. 2001, 1:85-94.
247. Hegymegi-Barakonyi B., Eros D., Szántai-Kis C., Breza N., Bánhegyi P., Szabó Gábor V., Várkondi E., Peták I., Orfi L., Kéri G. Tyrosine kinase inhibitors-small molecular weight compounds inhibiting EGFR. Curr. Opin. Mol. Ther. 2009, 3:308-321.
248. Mulshine J.L., Atkinson J.C., Greer R.O., Papadimitrakopoulou V.A., Van Waes C., Rudy S., Martin J.W., Steinberg S.M., Liewehr D.J., Avis I., Linnoila R.I., Hewitt S., Lippman S.M., Frye R., Cavanaugh P.F. Randomized, double-blind, placebo-controlled phase IIb trial of the cyclooxygenase inhibitor ketorolac as an oral rinse in oropharyngeal leukoplakia. Clin. Cancer Res. 2004, 10:1565-1573.
249. Lippman S.M., Gibson N., Subbaramaiah K., Dannenberg A.J. Combined targeting of the epidermal growth factor receptor and cyclooxygenase-2 pathways. Clin. Cancer Res. 2005, 11:6097-6099.
250. Gross A., McDonnell J.M., Korsmyer S.J. Bcl-2 family members and mitochondria in apoptosis. Genes Develop. 1999, 13:1891-1899.
251. Stoll C., Baretton G., Ahrens C., Lohrs U. Prognostic significance of apoptosis and associated factors in oral squamous cell carcinoma. Virchows Arch. 2000, 43:102-108.
252. Zhang Q., Thomas S.M., Xi S., Smithgall T.E., Siegfried J.M., Kamens J., Gooding W.E., Grandis Jennifer R. SRC family kinases mediate epidermal growth factor receptor ligand cleavage, proliferation, and invasion of head and neck cancer cells. Cancer Res. 2004, 17:6166-6173.
253. Aota K., Azuma M., Yamashita T., Tamatani T., Motegi K., Ishimaru N., Hayashi Y., Sato M. 5-Fluorouracil induces apoptosis through the suppression of NF-kappaB activity in human salivary gland cancer cells. Biochem. Biophys. Res. Commun. 2000, 273:1168-1174.
254. Azuma M., Tamatani T., Ashida Y., Takashima R., Harada K., Sato M. Cisplatin induces apoptosis in oral squamous carcinoma cells by the mitochondria-mediated but not the NF-kappaB-suppressed pathway. Oral Oncol. 2003, 39:282-289.
255. Mishima K., Nariai Y., Yoshimura Y. Carboplatin induces Fas (APO-1/CD95)-dependent apoptosis of human tongue carcinoma cells: sensitization for apoptosis by upregulation of FADD expression. Int. J. Cancer 2003, 105:593-600.
256. Gerber H.P., Ferrera N. Pharmacology and pharmacodynamics of bevacizumab as monotherapy or in combination with cytotoxic therapy in preclinical studies. Cancer Res. 2005, 65:671-680.
257. Cohen E.E., Davis D.W., Karrison T.G., Seiwert T.Y., Wong S.J., Nattam S., Kozloff M.F., Clark J.I., Yan D.H., Liu W., Pierce C., Dancey J.E., Stenson K., Blair E., Dekker A., Vokes E.E. Erlotinib and bevacizumab in patients with recurrent or metastatic squamous-cell carcinoma of the head and neck: a phase I/II study. Lancet Oncol. 2009, 3:247-257.
258. Savvides P., Greskovich J., Bokar J., Stepnick D.W., Fu P., Johnson F., Patel C., Wasman J., Remick S., Lavertu P. Phase II study of bevacizumab in combination with docetaxel and radiation in locally advanced squamous cell cancer of the head and neck (SCCHN). J. Clin. Oncol. 2007, 25(18s):6068.
259. Choong N.W., Haraf D.J., Cohen E.E., et al. Randomized phase II study of concomitant chemoradiotherapy with 5-fluorouracil-hydroxyurea (FHX) compared to FHX and bevacizumab (FHXB) in intermediate stage head and neck cancer (HNC). J. Clin. Oncol. 2007, 25(18s):6034.
260. Elser C., Siu L.L., Winquist E., Agulnik M., Pond G.R., Chin S.F., Francis P., Cheiken R., Elting J., McNabola A., Wilkie D., Petrenciuc O., Chen E.X. Phase II trial of sorafenib in patients with recurrent or metastatic squamous cell carcinoma of the head and neck or nasopharyngeal carcinoma. J. Clin. Oncol. 2007, 24:3766-3773.